Innovative Weight-Loss Drug Targets Brain's Plasticity for Enhanced Effectiveness

Researchers develop a new treatment combining GLP-1 and NMDA receptor blockers, showing promising results in preclinical trials.

The drug employs a 'Trojan Horse' method to deliver molecules directly to the brain's appetite control center.
Mice treated with the new drug lost twice as much weight as those on existing GLP-1 therapies.
Potential for lower dosages and reduced side effects compared to current treatments.
The approach could pave the way for new treatments for neurodegenerative and psychiatric disorders.
Human clinical trials are expected to start soon, with market availability projected in eight years.